Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation

BACKGROUND AND PURPOSES: Erythropoietin (EPO) has been shown to protect against myocardial infarction in animal studies by activating phosphatidylinositol-3 kinase (PI3K)/Akt and ERK1/2. However these pro-survival pathways are impaired in the diabetic heart. We investigated the ability of EPO to pro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mudalagiri, N R, Mocanu, M M, Di Salvo, C, Kolvekar, S, Hayward, M, Yap, J, Keogh, B, Yellon, D M
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2007
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2199395/
https://ncbi.nlm.nih.gov/pubmed/17952111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0707461
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars